Ashlee Jean Thomson

Ms. Ashlee Jean Thomson

Blood Cancer Program, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
ATAshlee Jean Thomson
Ashlee Jean Thomson
JRJacqueline Rehn
Jacqueline Rehn
DYDavid Yeung
David Yeung
JBJames Breen
James Breen
Deborah L WhiteDeborah L White
Deborah L White
Acute lymphoblastic leukaemia is a highly heterogeneous malignancy characterised by various genomic alterations that influence disease progression and therapeutic outcomes. Gene fusions involving the immunoglobulin heavy chain gene represent a complex and diverse category. These fusions often result in enhancer hijacking, upregulation of partner proto-oncogenes and contribute to leukemogenesis. This review highlights the mechanisms underlying IGH gene fusions, the critical role they play in ALL pathogenesis, and current detection technologies.

26 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ATAshlee Jean Thomson
Ashlee Jean Thomson
JRJacqueline Rehn
Jacqueline Rehn
SHSusan Heatley
Susan Heatley
Laura EadieLaura Eadie
Laura Eadie
Elyse C. PageElyse C. Page
Elyse C. Page
Deborah L WhiteDeborah L White
Deborah L White
B-cell acute lymphoblastic leukaemia (B-ALL) is characterised by diverse genomic alterations, the most frequent being gene fusions detected via transcriptomic analysis (mRNA-seq). Due to its hypervariable nature, gene fusions involving the Immunoglobulin Heavy Chain (IGH) locus can be difficult to detect with standard gene fusion calling algorithms and significant computational resources and analysis times are required. We aimed to optimize a gene fusion calling workflow to achieve best-case sensitivity for IGH gene fusion detection. Using Nextflow, we developed a simplified workflow containing the algorithms FusionCatcher, Arriba, and STAR-Fusion. We analysed samples from 35 patients harbouring IGH fusions (IGH::CRLF2 n = 17, IGH::DUX4 n = 15, IGH::EPOR n = 3) and assessed the detection rates for each caller, before optimizing the parameters to enhance sensitivity for IGH fusions. Initial results showed that FusionCatcher and Arriba outperformed STAR-Fusion (85–89% vs. 29% of IGH fusions reported). We found that extensive filtering in STAR-Fusion hindered IGH reporting. By adjusting specific filtering steps (e.g., read support, fusion fragments per million total reads), we achieved a 94% reporting rate for IGH fusions with STAR-Fusion. This analysis highlights the importance of filtering optimization for IGH gene fusion events, offering alternative workflows for difficult-to-detect high-risk B-ALL subtypes.